Therapeutic Targets in Diffuse Midline Gliomas-An Emerging Landscape.

Autor: Hayden E; Children's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Kensington 2052, Australia., Holliday H; Children's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Kensington 2052, Australia.; School of Women's and Children's Health, Faculty of Medicine, University of New South Wales, Kensington 2052, Australia., Lehmann R; Children's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Kensington 2052, Australia.; School of Women's and Children's Health, Faculty of Medicine, University of New South Wales, Kensington 2052, Australia., Khan A; Children's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Kensington 2052, Australia., Tsoli M; Children's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Kensington 2052, Australia.; School of Women's and Children's Health, Faculty of Medicine, University of New South Wales, Kensington 2052, Australia., Rayner BS; Children's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Kensington 2052, Australia.; School of Women's and Children's Health, Faculty of Medicine, University of New South Wales, Kensington 2052, Australia., Ziegler DS; Children's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Kensington 2052, Australia.; School of Women's and Children's Health, Faculty of Medicine, University of New South Wales, Kensington 2052, Australia.; Kids Cancer Centre, Sydney Children's Hospital, Randwick 2031, Australia.
Jazyk: angličtina
Zdroj: Cancers [Cancers (Basel)] 2021 Dec 13; Vol. 13 (24). Date of Electronic Publication: 2021 Dec 13.
DOI: 10.3390/cancers13246251
Abstrakt: Diffuse midline gliomas (DMGs) are invariably fatal pediatric brain tumours that are inherently resistant to conventional therapy. In recent years our understanding of the underlying molecular mechanisms of DMG tumorigenicity has resulted in the identification of novel targets and the development of a range of potential therapies, with multiple agents now being progressed to clinical translation to test their therapeutic efficacy. Here, we provide an overview of the current therapies aimed at epigenetic and mutational drivers, cellular pathway aberrations and tumor microenvironment mechanisms in DMGs in order to aid therapy development and facilitate a holistic approach to patient treatment.
Databáze: MEDLINE
Nepřihlášeným uživatelům se plný text nezobrazuje